Compare Meta Platforms Inc (META) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Meta Platforms Inc vs Merck & Co., Inc. — how do they compare? Meta Platforms Inc trades at $602.02 (market cap $1.53T), while Merck & Co., Inc. trades at $129.94 (market cap $321.77B). The key difference: Meta Platforms Inc is far larger — about 4.8× Merck & Co., Inc.'s market cap, and Merck & Co., Inc. pays the higher dividend (2.61%). Which is the better fit depends on your goals.
| META | MRK | |
|---|---|---|
Market Cap | $1.53T | $321.77B |
Volume | 24,093,972 | — |
Sector | Media | Health |
52-Week High | $790.00 | $131.84 |
52-Week Low | $525.72 | $77.60 |
Enterprise Value | $1.55T | $368.53B |
Dividend Yield | 0.35% | 2.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Meta Platforms trades at $594.92, up 0.48% with strong fundamentals including 81.75% gross margins and 29.84% net income margin. Recent Q1 2026 earnings beat expectations ($10.44 vs $6.70), though Q2 2026 missed ($6.18 vs $7.19). Technical indicators show bearish signals with current price near pivot point resistance at $598. The company maintains robust cash flow generation of $115.8B from operations in 2025.
Analyst consensus remains strongly bullish with 79% buy ratings and $761.95 price target, representing 28% upside. Key catalysts include AI leadership with Muse Spark launch and strong revenue growth trajectory. Risks include regulatory lawsuits, high capital expenditures, and competitive pressures in social media and AI markets.
Merck (MRK) trades at $130.9, up 1.81% today, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $140.36. Recent earnings beats and a 72.97% gross margin highlight strong profitability, while the acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline. The stock faces headwinds from a high P/E ratio of 104.34 and fluctuating cash flows.
The outlook is positive with robust fundamentals and strategic M&A, but valuation concerns and competitive pressures in pharma pose risks. Upside is likely if earnings growth continues, though investors should monitor debt levels and integration of acquisitions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Meta Platforms Inc
Meta Platforms Inc., doing business as Meta and previously known as Facebook Inc. It's a company that acts as a parent platform for Facebook, Messenger, Instagram, Whatsapp, Oculus and other subsidiaries. Among these platforms, Facebook is the number one social media platform in terms of the number of active users.
Read more on META →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
